RT Journal Article
SR Electronic
T1 Automated molecular testing of saliva for SARS-CoV-2 detection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.11.20170613
DO 10.1101/2020.08.11.20170613
A1 Nancy Matic
A1 Tanya Lawson
A1 Gordon Ritchie
A1 Aleksandra Stefanovic
A1 Victor Leung
A1 Sylvie Champagne
A1 Marc G. Romney
A1 Christopher F. Lowe
YR 2020
UL http://medrxiv.org/content/early/2020/08/14/2020.08.11.20170613.abstract
AB With surging global demand for increased SARS-CoV-2 testing capacity, clinical laboratories seek automated, high-throughput molecular solutions, particularly for specimen types which do not rely upon supply of specialized collection devices or viral transport media (VTM). Saliva was evaluated as a diagnostic specimen for SARS-CoV-2 using the cobas® SARS-CoV-2 Test on the cobas® 6800 instrument. Saliva specimens submitted from various patient populations under investigation for COVID-19 from March-July 2020 were processed in the laboratory with sterile phosphate-buffered saline in a 1:2 dilution and vortexed with glass beads. The processed saliva samples were tested using a commercial assay for detection of the SARS-CoV-2 E gene (LightMix®) in comparison to the cobas® SARS-CoV-2 Test. 22/64 (34.4%) of the saliva samples were positive for SARS-CoV-2. Positive and negative concordance between the LightMix® and cobas® assays were 100%. There was no cross-contamination of samples observed on the cobas® 6800. The overall invalid rate for saliva on the cobas® 6800 (1/128, 0.78%) was similar to the baseline invalid rate observed for nasopharyngeal swabs/VTM and plasma samples. Saliva is a feasible specimen type for SARS-CoV-2 testing on the cobas® 6800, with potential to improve turnaround time and enhance testing capacity.Competing Interest StatementN.M. reports honoraria related to speaker engagement outside the submitted work for Roche Molecular Systems, Inc. All other authors report no relevant conflicts of interest.Funding StatementNo external funding was received. This study was supported by Roche Diagnostics for a software upgrade of the cobas 6800, but no financial compensation was provided. Roche Diagnostics was not involved in the study design, implementation nor analysis of the data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Providence Health Care Research Ethics Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis article is a focused, brief report with the majority of data already presented in the manuscript.